They showed that PFS was significantly longer in patients with IDH-mutated WHO grade II and grade III gliomas, including astrocytomas and oligodendrogliomas, who achieved supratotal resection than in those who underwent gross total resection. The gene discussed is IDH1; the disease is central nervous system cancer.